image
C4 Therapeutics, Inc. CCCC
Healthcare - Biotechnology - NASDAQ - US
Watchlist
$ 1.48
-2.63 %
$ 105 M
Market Cap
-1.0
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Jul, 6, 2025.

The intrinsic value of one CCCC stock under the worst case scenario is HIDDEN Compared to the current market price of 1.48 USD, C4 Therapeutics, Inc. is HIDDEN

CCCC Intrinsic Value
HIDDEN
SHOW

This DCF valuation model was last updated on Jul, 6, 2025.

The intrinsic value of one CCCC stock under the base case scenario is HIDDEN Compared to the current market price of 1.48 USD, C4 Therapeutics, Inc. is HIDDEN

CCCC Intrinsic Value
HIDDEN
SHOW

This DCF valuation model was last updated on Jul, 6, 2025.

The intrinsic value of one CCCC stock under the best case scenario is HIDDEN Compared to the current market price of 1.48 USD, C4 Therapeutics, Inc. is HIDDEN

CCCC Intrinsic Value
HIDDEN
SHOW
2. FUNDAMENTAL ANALYSIS

Price Chart CCCC

image
1M -3%
6M -161%
1Y -282%
3Y -562%
5Y --%
All
$4.5$4.5$4.0$4.0$3.5$3.5$3.0$3.0$2.5$2.5$2.0$2.0$1.5$1.5$1.0$1.015 Jan15 JanFeb '25Feb '2515 Feb15 FebMar '25Mar '2515 Mar15 MarApr '25Apr '2515 Apr15 AprMay '25May '2515 May15 MayJun '25Jun '2515 Jun15 JunJul '25Jul '25
FINANCIALS
35.6 M REVENUE
71.44%
Growth Rates
1Year 71.44%
3Years -8.06%
5Years 10.72%
7Years 0.00%
10Years 0.00%
-120 M OPERATING INCOME
13.97%
Growth Rates
1Year 13.97%
3Years -13.35%
5Years -27.53%
7Years 0.00%
10Years 0.00%
-105 M NET INCOME
20.51%
Growth Rates
1Year 20.51%
3Years -7.88%
5Years -25.30%
7Years 0.00%
10Years 0.00%
-65.2 M OPERATING CASH FLOW
39.01%
Growth Rates
1Year 39.01%
3Years 9.17%
5Years -16.78%
7Years 0.00%
10Years 0.00%
-51.3 M INVESTING CASH FLOW
-32.38%
Growth Rates
1Year -32.38%
3Years 35.30%
5Years -99.56%
7Years 0.00%
10Years 0.00%
45.3 M FINANCING CASH FLOW
-0.34%
Growth Rates
1Year -0.34%
3Years -35.81%
5Years 184.32%
7Years 0.00%
10Years 0.00%
7.24 M REVENUE
39.81%
Growth Rates
1Year 71.44%
3Years -8.06%
5Years 10.72%
7Years 0.00%
10Years 0.00%
-29.2 M OPERATING INCOME
22.66%
Growth Rates
1Year 13.97%
3Years -13.35%
5Years -27.53%
7Years 0.00%
10Years 0.00%
-26.3 M NET INCOME
23.87%
Growth Rates
1Year 20.51%
3Years -7.88%
5Years -25.30%
7Years 0.00%
10Years 0.00%
-33.3 M OPERATING CASH FLOW
-85.62%
Growth Rates
1Year 39.01%
3Years 9.17%
5Years -16.78%
7Years 0.00%
10Years 0.00%
29.1 M INVESTING CASH FLOW
113.06%
Growth Rates
1Year -32.38%
3Years 35.30%
5Years -99.56%
7Years 0.00%
10Years 0.00%
-46 K FINANCING CASH FLOW
-41.07%
Growth Rates
1Year -0.34%
3Years -35.81%
5Years 184.32%
7Years 0.00%
10Years 0.00%
Balance Sheet C4 Therapeutics, Inc.
image
Current Assets 258 M
Cash & Short-Term Investments 245 M
Receivables 3.1 M
Other Current Assets 9.76 M
Non-Current Assets 91.8 M
Long-Term Investments 22.4 M
PP&E 63.4 M
Other Non-Current Assets 6.1 M
70.05 %2.79 %6.40 %18.13 %Total Assets$349.6m
Current Liabilities 45.2 M
Accounts Payable 1.33 M
Short-Term Debt 11.5 M
Other Current Liabilities 32.3 M
Non-Current Liabilities 88.4 M
Long-Term Debt 60 M
Other Non-Current Liabilities 28.5 M
8.64 %24.17 %44.89 %21.30 %Total Liabilities$133.6m
EFFICIENCY
Earnings Waterfall C4 Therapeutics, Inc.
image
Revenue 35.6 M
Cost Of Revenue 0
Gross Profit 35.6 M
Operating Expenses 155 M
Operating Income -120 M
Other Expenses -14.3 M
Net Income -105 M
40m40m20m20m00(20m)(20m)(40m)(40m)(60m)(60m)(80m)(80m)(100m)(100m)(120m)(120m)36m036m(155m)(120m)14m(105m)RevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
100.00% GROSS MARGIN
100.00%
Averages
1Year 100.00%
3Years -97.15%
5Years -66.23%
7Years -71.68%
10Years 0.00%
-336.15% OPERATING MARGIN
-336.15%
Averages
1Year -336.15%
3Years -474.18%
5Years -356.81%
7Years -290.64%
10Years 0.00%
-295.96% NET MARGIN
-295.96%
Averages
1Year -295.96%
3Years -447.03%
5Years -345.77%
7Years -281.35%
10Years 0.00%
-48.76% ROE
-48.76%
Averages
1Year -48.76%
3Years -48.78%
5Years -38.41%
7Years -20.27%
10Years 0.00%
-30.12% ROA
-30.12%
Averages
1Year -30.12%
3Years -31.56%
5Years -25.65%
7Years -23.97%
10Years 0.00%
-37.90% ROIC
-37.90%
Averages
1Year -37.90%
3Years -37.15%
5Years -29.31%
7Years -28.98%
10Years 0.00%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis C4 Therapeutics, Inc.
image
60m60m40m40m20m20m00(20m)(20m)(40m)(40m)(60m)(60m)(80m)(80m)(100m)(100m)(120m)(120m)20192019202020202021202120222022202320232024202420252025
Net Income -105 M
Depreciation & Amortization 1.82 M
Capital Expenditures -180 K
Stock-Based Compensation 29.7 M
Change in Working Capital 7.65 M
Others 101 K
Free Cash Flow -65.3 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets C4 Therapeutics, Inc.
image
Wall Street analysts predict an average 1-year price target for CCCC of $14 , with forecasts ranging from a low of $9 to a high of $20 .
CCCC Lowest Price Target Wall Street Target
9 USD 508.11%
CCCC Average Price Target Wall Street Target
14 USD 845.95%
CCCC Highest Price Target Wall Street Target
20 USD 1251.35%
Price
Max Price Target
Min Price Target
Average Price Target
2020181816161414121210108866442200Aug '24Aug '24Oct '24Oct '24Nov '24Nov '2420252025Feb '25Feb '25Apr '25Apr '25Jun '25Jun '25Jul '25Jul '25Aug '25Aug '25Oct '25Oct '25Nov '25Nov '2520262026Feb '26Feb '26Apr '26Apr '26Jun '26Jun '26Jul '26Jul '26
4. DIVIDEND ANALYSIS
5. COMPETITION
slide 2 of 7
6. Ownership
Insider Ownership C4 Therapeutics, Inc.
image
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
3.65 K USD 1
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
C4 Therapeutics: An Entry Point If There's Ever Going To Be One CCCC's valuation is unjustifiably low, trading at half its liquidity despite a promising pipeline and no imminent cash crisis. Lead candidate cemsidomide shows encouraging early efficacy and tolerability in heavily pretreated multiple myeloma patients, with key data readouts expected in Q3 2025. Cost controls and restructuring have extended CCCC's cash runway into 2027, reducing dilution risk and supporting ongoing development and partnerships. seekingalpha.com - 3 weeks ago
C4 Therapeutics, Inc. (CCCC) Reports Q1 Loss, Tops Revenue Estimates C4 Therapeutics, Inc. (CCCC) came out with a quarterly loss of $0.37 per share versus the Zacks Consensus Estimate of a loss of $0.48. This compares to loss of $0.41 per share a year ago. zacks.com - 2 months ago
C4 Therapeutics Reports First Quarter 2025 Financial Results and Recent Business Highlights Updated Cemsidomide Multiple Myeloma Data Further Demonstrate Compelling Response Rates at Multiple Doses and Potential for Best-in-Class Profile; 50% ORR Observed at the Highest Dose Level of 100 µ g, Including One Patient With a Minimal Residual Disease Negative Complete Response ; 40% ORR Achieved at the 75 µ g Dose Level globenewswire.com - 2 months ago
C4 Therapeutics (CCCC) Loses -21.9% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner C4 Therapeutics (CCCC) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock. zacks.com - 4 months ago
C4 Therapeutics (CCCC) Loses -26.18% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner The heavy selling pressure might have exhausted for C4 Therapeutics (CCCC) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal. zacks.com - 4 months ago
C4 Therapeutics, Inc. (CCCC) Reports Q4 Loss, Lags Revenue Estimates C4 Therapeutics, Inc. (CCCC) came out with a quarterly loss of $0.49 per share versus the Zacks Consensus Estimate of a loss of $0.44. This compares to loss of $0.68 per share a year ago. zacks.com - 4 months ago
C4 Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights Planning Activities Are Ongoing for Next Phase of Cemsidomide Clinical Development in Multiple Myeloma and Non-Hodgkin's Lymphoma; Trials Expected to Initiate in Early 2026 globenewswire.com - 4 months ago
C4 Therapeutics (CCCC) Loses -23.14% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner The heavy selling pressure might have exhausted for C4 Therapeutics (CCCC) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal. zacks.com - 4 months ago
C4 Therapeutics to Participate in Upcoming March Investor Conferences WATERTOWN, Mass., Feb. 24, 2025 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today announced that C4T management will participate in two upcoming March investor conferences. globenewswire.com - 4 months ago
Here's Why C4 Therapeutics (CCCC) Is a Great 'Buy the Bottom' Stock Now C4 Therapeutics (CCCC) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term. zacks.com - 6 months ago
C4 Therapeutics Presents Cemsidomide Phase 1 Data at the American Society for Hematology (ASH) Annual Meeting that Demonstrated Potential to Become Best-in-Class IKZF1/3 Degrader In Multiple Myeloma, Cemsidomide in Combination with Dexamethasone at Highest Dose Level Explored to Date Achieved 36 Percent Overall Response Rate (ORR) and 45 Percent Clinical Benefit Rate (CBR); Responses Seen Across All Dose Levels globenewswire.com - 7 months ago
C4 Therapeutics Appoints Accomplished Oncology Executive Steve Hoerter to Board of Directors Hoerter Brings Over Three Decades of Oncology Commercialization and Leadership Experience Appointment Underscores Continued Transformation of Board to Lead C4T into Next Phase of Pipeline Progress WATERTOWN, Mass., Nov. 20, 2024 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today announced the continued evolution of its Board of Directors with the appointment of Steve Hoerter as a director. globenewswire.com - 7 months ago
8. Profile Summary

C4 Therapeutics, Inc. CCCC

image
COUNTRY US
INDUSTRY Biotechnology
MARKET CAP $ 105 M
Dividend Yield 0.00%
Description C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting IKZF1 and IKZF3 for multiple myeloma and non-Hodgkin lymphomas, including peripheral T-cell lymphoma and mantle cell lymphoma. The company is also developing CFT8634, an orally bioavailable BiDAC degrader of BRD9, a protein target for synovial sarcoma and SMARCB1-deleted solid tumors; CFT1946, an orally bioavailable BiDAC degrader targeting V600X mutant BRAF to treat melanoma, non-small cell lung cancer (NSCLC), colorectal cancer, and other solid malignancies; CFT8919, an orally bioavailable, allosteric, and mutant-selective BiDAC degrader of epidermal growth factor receptor, or EGFR, with an L858R mutation in NSCLC; and earlier stage programs comprising RET degraders for the treatment of various cancers. C4 Therapeutics, Inc. has strategic collaborations with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; Biogen MA, Inc.; and Calico Life Sciences LLC. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.
Contact 490 Arsenal Way, Watertown, MA, 02472 https://www.c4therapeutics.com
IPO Date Oct. 2, 2020
Employees 110
Officers Ms. Courtney Solberg Senior Manager of Investor Relations Ms. Kendra Adams Chief Financial Officer & Treasurer Mr. Mark Mossler Chief Accounting Officer Dr. Kenneth C. Anderson M.D., Ph.D. Co-Founder, Independent Director & Member of Scientific Advisory Board Dr. Nathanael S. Gray Ph.D. Co-Founder & Member of Scientific Advisory Board Dr. Leonard M. J. Reyno M.D. Chief Medical Officer Mr. Andrew J. Hirsch M.B.A. Chief Executive Officer, President & Director Ms. Jolie M. Siegel J.D. Chief Legal Officer & Corporate Secretary Ms. Kelly A. Schick Chief People Officer Ms. Paige Mahaney Ph.D. Chief Scientific Officer